LivaNova (NASDAQ:LIVN - Get Free Report) had its target price lowered by equities research analysts at Stifel Nicolaus from $72.00 to $60.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price target would suggest a potential upside of 44.13% from the stock's current price.
LIVN has been the topic of a number of other research reports. Mizuho dropped their price target on LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, October 31st. Robert W. Baird lifted their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Wolfe Research downgraded shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday. Needham & Company LLC decreased their price objective on shares of LivaNova from $75.00 to $64.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, LivaNova presently has an average rating of "Buy" and an average target price of $64.20.
Read Our Latest Research Report on LIVN
LivaNova Price Performance
Shares of NASDAQ LIVN traded up $0.70 during mid-day trading on Wednesday, reaching $41.63. The company had a trading volume of 807,916 shares, compared to its average volume of 582,675. The company has a 50-day moving average price of $47.40 and a two-hundred day moving average price of $49.49. The stock has a market cap of $2.26 billion, a PE ratio of 99.12 and a beta of 1.00. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova has a 1-year low of $40.37 and a 1-year high of $64.47.
Insider Buying and Selling
In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.27% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On LivaNova
Large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its stake in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after buying an additional 219 shares in the last quarter. Sterling Capital Management LLC raised its holdings in shares of LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after purchasing an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division raised its holdings in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after purchasing an additional 720 shares in the last quarter. Vestcor Inc bought a new position in shares of LivaNova during the 4th quarter valued at $204,000. Finally, Optimize Financial Inc bought a new stake in shares of LivaNova during the 4th quarter worth about $208,000. Institutional investors own 97.64% of the company's stock.
About LivaNova
(
Get Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Articles
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
